A potent platelet aggregation inducer from Trimeresurus gramineus snake venom.
A potent platelet aggregation inducer (platelet aggregoserpentin) was purified from Trimeresurus gramineus snake venom by DEAE-Sephadex A-50 and Sephacryl S-300 column chromatography. It was homogeneous as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It elicited dose-dependently platelet aggregation and serotonin release reaction in rabbit platelet-rich plasma and platelet suspension. Exogenous calcium was required for its activity. Creatine phosphate/creatine phosphokinase and apyrase showed no significant inhibitory effect on aggregoserpentin-induced platelet aggregation in platelet suspension. Aggregoserpentin induced aggregation in ADP-refractory platelet-rich plasma. It caused no detectable malonic dialdehyde formation in the process of platelet aggregation. Indomethacin did not inhibit aggregoserpentin-induced platelet aggregation. Mepacrine abolished preferentially its aggregating activity, while prostaglandin E1 completely blocked both aggregoserpentin-induced aggregation and release reaction. Furthermore, platelet aggregoserpentin lowered basal and prostaglandin E1-stimulated cAMP levels in platelet suspension. Nitroprusside inhibited both its aggregating and releasing activity, while verapamil preferentially blocked its aggregating activity. It is concluded that aggregoserpentin activated platelets through lowering cAMP levels or the activation of endogenous phospholipase A2, resulting in the formation of platelet activating factor, but not of prostaglandins.
D000227:Adenine Nucleotides / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D000242:Cyclic AMP / Q000502:physiology; D007213:Indomethacin / Q000494:pharmacology; D008315:Malondialdehyde / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D010974:Platelet Aggregation / Q000187:drug effects; D011458:Prostaglandins E / Q000502:physiology; D011509:Proteoglycans / Q000302:isolation & purification*; D011817:Rabbits; D014700:Verapamil / Q000494:pharmacology; D014757:Viper Venoms / Q000032:analysis* / Q000494:pharmacology
D000227:Adenine Nucleotides; D011458:Prostaglandins E; D011509:Proteoglycans; D014757:Viper Venoms; D009599:Nitroprusside; D008315:Malondialdehyde; C026064:aggregoserpentin; D014700:Verapamil; D000242:Cyclic AMP; D010741:Phospholipases A; D054467:Phospholipases A2; D000241:Adenosine; D002118:Calcium; D007213:Indomethacin